NBIX vs PLUS · P/E 45, rev $2.36B vs P/E 17, rev $2.07B
Neurocrine Biosciences Inc (NBIX) versus ePlus inc (PLUS) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Not investment advice. Open the NBIX and PLUS stock pages for the full models.
Not investment advice.